Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection

We estimated 30-day all-cause and Clostridium difficile infection (CDI)–associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, nota...

Descripción completa

Detalles Bibliográficos
Autores principales: Prabhu, Vimalanand S, Cornely, Oliver A, Golan, Yoav, Dubberke, Erik R, Heimann, Sebastian M, Hanson, Mary E, Liao, Jane, Pedley, Alison, Dorr, Mary Beth, Marcella, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848255/
https://www.ncbi.nlm.nih.gov/pubmed/30060024
http://dx.doi.org/10.1093/cid/cix523
_version_ 1783305847946870784
author Prabhu, Vimalanand S
Cornely, Oliver A
Golan, Yoav
Dubberke, Erik R
Heimann, Sebastian M
Hanson, Mary E
Liao, Jane
Pedley, Alison
Dorr, Mary Beth
Marcella, Stephen
author_facet Prabhu, Vimalanand S
Cornely, Oliver A
Golan, Yoav
Dubberke, Erik R
Heimann, Sebastian M
Hanson, Mary E
Liao, Jane
Pedley, Alison
Dorr, Mary Beth
Marcella, Stephen
author_sort Prabhu, Vimalanand S
collection PubMed
description We estimated 30-day all-cause and Clostridium difficile infection (CDI)–associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).
format Online
Article
Text
id pubmed-5848255
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58482552018-03-21 Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection Prabhu, Vimalanand S Cornely, Oliver A Golan, Yoav Dubberke, Erik R Heimann, Sebastian M Hanson, Mary E Liao, Jane Pedley, Alison Dorr, Mary Beth Marcella, Stephen Clin Infect Dis Brief Reports We estimated 30-day all-cause and Clostridium difficile infection (CDI)–associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II). Oxford University Press 2017-10-01 2017-08-11 /pmc/articles/PMC5848255/ /pubmed/30060024 http://dx.doi.org/10.1093/cid/cix523 Text en © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Reports
Prabhu, Vimalanand S
Cornely, Oliver A
Golan, Yoav
Dubberke, Erik R
Heimann, Sebastian M
Hanson, Mary E
Liao, Jane
Pedley, Alison
Dorr, Mary Beth
Marcella, Stephen
Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
title Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
title_full Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
title_fullStr Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
title_full_unstemmed Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
title_short Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
title_sort thirty-day readmissions in hospitalized patients who received bezlotoxumab with antibacterial drug treatment for clostridium difficile infection
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848255/
https://www.ncbi.nlm.nih.gov/pubmed/30060024
http://dx.doi.org/10.1093/cid/cix523
work_keys_str_mv AT prabhuvimalanands thirtydayreadmissionsinhospitalizedpatientswhoreceivedbezlotoxumabwithantibacterialdrugtreatmentforclostridiumdifficileinfection
AT cornelyolivera thirtydayreadmissionsinhospitalizedpatientswhoreceivedbezlotoxumabwithantibacterialdrugtreatmentforclostridiumdifficileinfection
AT golanyoav thirtydayreadmissionsinhospitalizedpatientswhoreceivedbezlotoxumabwithantibacterialdrugtreatmentforclostridiumdifficileinfection
AT dubberkeerikr thirtydayreadmissionsinhospitalizedpatientswhoreceivedbezlotoxumabwithantibacterialdrugtreatmentforclostridiumdifficileinfection
AT heimannsebastianm thirtydayreadmissionsinhospitalizedpatientswhoreceivedbezlotoxumabwithantibacterialdrugtreatmentforclostridiumdifficileinfection
AT hansonmarye thirtydayreadmissionsinhospitalizedpatientswhoreceivedbezlotoxumabwithantibacterialdrugtreatmentforclostridiumdifficileinfection
AT liaojane thirtydayreadmissionsinhospitalizedpatientswhoreceivedbezlotoxumabwithantibacterialdrugtreatmentforclostridiumdifficileinfection
AT pedleyalison thirtydayreadmissionsinhospitalizedpatientswhoreceivedbezlotoxumabwithantibacterialdrugtreatmentforclostridiumdifficileinfection
AT dorrmarybeth thirtydayreadmissionsinhospitalizedpatientswhoreceivedbezlotoxumabwithantibacterialdrugtreatmentforclostridiumdifficileinfection
AT marcellastephen thirtydayreadmissionsinhospitalizedpatientswhoreceivedbezlotoxumabwithantibacterialdrugtreatmentforclostridiumdifficileinfection

Ejemplares similares